This study could be expanded with the evaluation of the expression of the TAM receptor in metastatic melanomas and the screening of the mutation of the oncogenes nRAS, BRAF, and c-KIT with subsequently therapeutic implications in the era of the “targeted therapy.” The gene discussed is KIT; the disease is melanoma.